Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q1 2024 Earnings Presentation
24 slides from Expres2ion Biotech Holding Ab's earnings presentation, May 16, 2024
Slide 1: healthier wo
healthier wo
Slide 2: Disclaimer
expreSceion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentat
Slide 3: Management discussion & analysis
Management discussion & analysis
Slide 4: Key updates thus far in 2024
expreSceion BIOTECH Key updates thus far in 2024 February May + Associated company! AdaptVac ApS + ExpreS2ion announces rights issue of announces milestone payment receipt units of approximately SEK 60 million, from Bavarian Nordic for ABNCoV2 primarily to fund ES2B-C001 clinical phase Ill study com
Slide 5: Vaccine pipeline
Vaccine pipeline expreSceion BIOTECH Discovery Lead opt CTA-enabling Phi Ph2 Ph3. Market size ES2B-C001 a, >€10 HER2+ breast cancer Incology Billion! (therapeutic) ee bs e @ ES2B one Infectious >€2 Pee omecaioviris disease Billion? ae (prevention) Exploratory >€2 Undisclosed Billion’ Piatt ertvhate
Slide 6: ES2B-C001 therapeutic breast cancer vaccine: Investment highlights
expreSceion BIOTECH ES2B-COO1 therapeutic breast cancer vaccine Investment highlights a Unmet medical need < N 7 Market size < NN _ Technical validation < Experienced team < * ExpreS2ion is developing a therapy for HER2+ breast cancer, the most common cancer * Obtainable market conservatively estima
Slide 7: Advancing our proprietary pipeline: ES2B-C001
expreSceion BIOTECH Advancing our proprietary pipeline ES2B-CO00!1: Therapeutic HER2+ breast cancer vaccine BEE + Study completed early 2024 + Final report signed in April -—— iemistry, Manufacturing and Controls + Viral Clearance Study completed early 2024 + Drug substance manufacturing completed i
Slide 8: Advancing our proprietary pipeline: ES2B-C002 CMV vaccine
expreSeion BIOTECH Advancing our proprietary pipeline ES2B-l002: Cytomegalovirus vaccine candidate @ + Overall project status @ + Project is on track @ + All sub-teams formed, and respective activities initiated + Advancing through Al-driven candidate selection + Scientific progress + Antigen discov
Slide 9: ExpreS2 platform collaborations
ExpreS2 platform collaborations + numerous additional pharmaceutical and biotech protein production projects “ Influenza Through partnership with Copenhagen University bake Nipah and filovirus Through participation in VICI-Disease consortium cs Cytomegalovirus ExpreS2ion has first right to license e
Slide 10: Univ. of Oxford malaria vaccine candidates
Univ. of Oxford malaria vaccine candidates Advancing through clinical testing expreSceion BIOTECH Trial abbreviation Phase _ Sites Vaccines in trial Trial status Year started RHS.1 in Matrix-M Vaccinations VACO089 la Oxford, UK R78C in Matrix-M eneraiins 2023 MRC Unit, RHS.2 in Matrix-M Vaccinations
Slide 11: Upcoming events
expreSceion BIOTECH Upcoming events Opportunities to learn more about specific projects and interact with management 30 May, 11:00 CET * The BioStock Global Forum = 4 June mtiicim °H.C. Andersen Life Science Seminar CAPITAL 1
Slide 12: Financial results
Financial results
Slide 13: Summary of 2024 first quarter results
expreSceion BIOTECH Summary of 2024 first quarter results Q1 2024 Q1 2023 % Change Key income statement figures, SEK ‘000s Operating income 1,558 2,590 -40% Profit/loss after financial items -13,839 -30,282 54% Profit/loss 12,853 -26,308 -51% Key balance sheet figures, SEK ‘000s Cash balance, end of
Slide 14: Net sales and other operating income
3,000 3,000 3,000 Net sales Other operating income 2,000 2,000 2,000 1,000 1,000 1,000 0 0 0 1Q22 3Q22 1Q23 3Q23 1Q24 1Q22 3Q22 1Q23 3Q23 1Q24 1Q22 3Q22 1Q23 3Q23 1Q24
Slide 15: -10,000 -20,000 -30,000 -40,000 -50,000 -60,000 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23
0 -10,000 -20,000 -30,000 -40,000 -50,000 -60,000 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24
Slide 16: 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 1Q22 2Q22 3Q22 4Q22 1Q23
0 0 -10,000 -10,000 -20,000 -20,000 -30,000 -30,000 -40,000 -40,000 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24
Slide 17: 2023 2024 2022 2023 -12,853 -30,000 -26,308 -30,000 -60,000 -60,000 -90,000 -90,000 -95,989 -120,000
2023 2024 2022 2023 0 0 -12,853 -30,000 -26,308 -30,000 -60,000 -60,000 -90,000 -90,000 -95,989 -120,000 -120,000 -118,605 -150,000 -150,000
Slide 18: Cash development December 2023 to March 2024
70 60 50 40 30 20 10 0 December 2023 New Capital Operations and Investment Currency changes March 2024 Activities
Slide 19: 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24
200 168 150 150 125 111 100 88 77 72 58 60 50 0 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24
Slide 20: Rights issue
Rights issue
Slide 21: Rights issue
Rights issue * Rights issue announced 2 May 2024 + Amounting to approximately SEK 60 million, primarily to fund ES2B-C001 clinical phase initiation and progression * Subscription intentions and guarantee commitments of approximately 50%, or SEK 30 million * Includes TO 10 and TO 11 warrants, for sub
Slide 22: Rights issue: Structure and timeline
expreSeion BIOTECH Rights issue Structure and timeline * Existing EXPRS2 shareholders as of the record date, 10 June 2024, will receive seven (7) unit rights for each existing share * Six (6) unit rights entitle to subscription of one (1) Unit in the Rights Issue, for SEK 1.00 per Unit * Each Unit c
Slide 23: Q&A
Slide 24: Investor Relations
Investor Relations
ExpreS2ion Biotech Holding — Q1 2024 Earnings Presentation on 6ix